NGEN
SinkerNervGen Pharma Corp. · Healthcare · Canada · $154M cap · $799K/day traded
$1.63 +20.7% · close 12 Nov · scored 13 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 13 Nov 2026, the MoatMap Score for NervGen Pharma Corp. (NGEN) is 4/100, ranked against 25,000+ stocks in 38 markets (Quality 28, Value 21, Momentum 20, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT NERVGEN PHARMA CORP.
Read
NervGen Pharma Corp. is a clinical-stage biotechnology company developing a novel therapeutic to promote nervous system repair and regeneration, primarily for spinal cord injury. It focuses on a challenging and underserved area of neuroregeneration, with a unique approach to blocking protein tyrosine phosphatase sigma (PTPσ). NervGen is a clinical-stage biotech firm targeting a high unmet medical need with a potentially transformative therapy for neurological damage.
FINANCIAL SUMMARY (USD)
Reported in CAD
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.32 | -0.30 | -0.28 | -0.26 | -0.44 | — | -0.57 | -0.35 | -0.24 | — |
| Shares | 46.2M | 58.8M | 59.6M | 70.3M | 79.6M | +72.4% | 107.5M | — | — | — |
| Debt | 0 | 0.2M | 0.1M | 73.6K | 6.1K | -69.2% | — | — | — | — |
| Equity | 16.8M | 9.9M | -1.5M | 1.8M | 2.5M | -37.7% | — | — | — | — |
| Op CF | -8.3M | -13.7M | -8.4M | -12.3M | -14.0M | — | -18.2M | — | — | — |
| Inv CF | -45.1K | -16.2K | -0.1M | 43.0K | 72.2K | — | — | — | — | — |
| Fin CF | 19.6M | 17.4M | 0.6M | 16.6M | 17.0M | — | — | — | — | — |
Made a new 52-week low 7 trading days ago, 74% below its 52-week high. The fall has not stopped yet.
Swung more than 91% of stocks we rank over the past year (volatility 85% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NGEN are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| NGEN | NervGen Pharma Corp.(you) | $154M | 4 |
| MSCL.TO | Satellos Bioscience Inc. | $138M | 12 |
| PMN | ProMIS Neurosciences, Inc. | $75M | 3 |
| MIST | Milestone Pharmaceuticals Inc. | $81M | 1 |
| OBI.L | Ondine Biomedical Inc. | $73M | 5 |
| ENGN | enGene Therapeutics Inc. | $105M | 13 |
| EDSA | Edesa Biotech, Inc. | $51M | 2 |
| BETR.CN | BetterLife Pharma Inc. | $99M | 23 |
| SONA.CN | Sona Nanotech Inc. | $29M | 4 |
| SVA.TO | Sernova Biotherapeutics Inc | $30M | 6 |
Peer medians: ROE -27.0% · P/E 19.0x · Gross margin 51.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.